Cardiff Oncology Data Bolsters First-Line CRC Program, Signals Registrational Path

Event summary

  • Cardiff Oncology reported a Phase 2 trial (CRDF-004) showing a 72.2% objective response rate (ORR) with onvansertib + FOLFIRI/bev in first-line RAS-mutated mCRC, compared to 43.2% with standard of care.
  • The trial demonstrated a statistically significant improvement in progression-free survival (HR: 0.37, p<0.05) with the onvansertib combination.
  • Cardiff Oncology appointed Mani Mohindru as interim CEO and Brigitte Lindsay as Chief Accounting Officer in January 2026, amidst a search for permanent executive leadership.
  • The company ended 2025 with $58.3 million in cash, projecting sufficient runway into Q1 2027.
  • Clinical data on onvansertib monotherapy in chronic myelomonocytic leukemia (CMML) were presented at ASH 2025, showing preliminary efficacy in approximately 40% of patients.

The big picture

Cardiff Oncology's Phase 2 data represent a potentially significant advancement in first-line treatment for RAS-mutated mCRC, a market with high unmet need and limited innovation in over two decades. The robust ORR and PFS improvements, coupled with the planned registrational program, position onvansertib as a potential new standard of care. However, the company's reliance on FDA approval and the ongoing executive leadership transition introduce key risks that investors must monitor.

What we're watching

Regulatory Approval
The FDA discussions and subsequent registrational plans will be critical to determining the timeline and likelihood of onvansertib's approval, which will significantly impact Cardiff's valuation.
Execution Risk
The transition to late-stage development and the search for a permanent CEO and CFO introduce execution risks that could delay the program or impact operational efficiency.
Competitive Landscape
The success of onvansertib will depend on its ability to maintain a competitive advantage over existing and emerging therapies in the RAS-mutated mCRC space, particularly given the established use of FOLFOX and FOLFIRI.

Related topics

Biotechnology